Next 10 |
2024-05-10 07:17:48 ET More on Pacira BioSciences Pacira Biosciences announces proposed offering of $250M aggregate principal amount of convertible senior notes Pacira BioSciences up 12% on stock buyback, Q1 top-line beat Read the full article on Seeking Alpha ...
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule...
2024-05-08 16:36:45 ET More on Pacira BioSciences Pacira BioSciences up 12% on stock buyback, Q1 top-line beat Pacira BioSciences GAAP EPS of $0.54 beats by $0.15, revenue of $181.2M beats by $0.34M Read the full article on Seeking Alpha For further details s...
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement...
2024-05-08 13:08:11 ET More on Pacira BioSciences Pacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript Pacira BioSciences, Inc. (PCRX) Q4 2023 Earnings Call Transcript Pacira ...
2024-05-07 21:14:02 ET Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Conference Call May 07, 2024, 04:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charles Reinhart - Chief Financial Officer Jona...
2024-05-07 17:29:16 ET More on Pacira BioSciences Pacira BioSciences, Inc. (PCRX) Q4 2023 Earnings Call Transcript Pacira BioSciences GAAP EPS of $0.54 beats by $0.15, revenue of $181.2M beats by $0.34M Pacira BioSciences Q4 2023 Earnings Preview Seeking Alph...
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of...
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the ev...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule...
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement...
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of...